With Shasun Pharmaceutical's UK subsidiary reporting profits for the first time, Shasun reported a six-fold jump in net profit to Rs 27 crore in 2010-11 on a consolidated basis compared with Rs 4 crore the previous year.

Shasun Pharmaceuticals had acquired the ailing UK pharma company, Rhodia, in 2006, which had been in the red for the previous five years.

For 2010-11, Rhodia, since renamed Shasun Pharma Solutions, posted a Rs 20-crore profit on a turnover of Rs 271 crore. It had reported loss of Rs 17 crore on a turnover of Rs 243 crore the previous year. Shasun's consolidated gross revenue moved up 5 per cent to Rs 840 crore for the year ending March 31, 2011.

Shasun has not provided financial results for the January-March quarter. However, back of the envelope calculations show that the company made a net profit of Rs 15.7 crore for the quarter (standalone, non-consolidated), compared with a net profit of Rs 9 crore for the same period the previous year. Revenue fell to Rs 140 crore for the quarter ending March 31, 2011, against Rs 153 crore for the same period last year.

Stoppage of operations in Cuddalore plant for 45 days and increase in raw materials led Shasun Pharmaceuticals to post lower profits at Rs 5 crore for the year ending March 31, 2011, compared with Rs 22 crore the previous year. The company had shut operations due to bromine fume leakage in storage area in the plant.

Total revenue of the company increased to Rs 568 crore in 2010-11 (Rs 548 crore). Shares of Shasun closed at Rs 79, up 3.34 per cent on the BSE.

Related Topics
comment COMMENT NOW